Zivo Bioscience, Inc. · OTC:ZIVO

Zivo Bioscience — Shareholder Meeting (May 2019)

44 slides from Zivo Bioscience's shareholder meeting presentation, May 1, 2019

  1. Slide 1: President's Report to Shareholders

    EXHIBIT 99.1 May 1, 2019 PRESIDENT'S REPORT TO SHAREHOLDERS Good morning. Welcome to attendees here in person and those on the call-in line. And, welcome to our board of directors, company principals and consultants in attendance or online today. My name is Andrew Dahl, president and chief executive

  2. Slide 2: President's Report (continued)

    human use of our dried algae as a food and beverage ingredient, which allows us to immediately sell our dried algae in the US. Ramping up production is capital- intensive, which is why the Company issued its proxy and this most recent shareholder vote to increase the shares available for investment,

  3. Slide 3: President's Report (continued)

    protections in China. A similar process was launched in Taiwan to protect our intellectual property there in late 2018. By our calculations, 40 contracted producers in southwest China and Inner Mongolia can produce up to 11,000 metric tons annually, with a direct-to-producer price of $12,000 per ton

  4. Slide 4: President's Report: poultry market opportunity

    successful once we figured out the proper processing of the algal biomass. I don’t think I can overstate the importance of these tests, what impact they may have on the company’s near-term and long-term prospects and the potential impact on the entire poultry industry. We believe the poultry market

  5. Slide 5: President's Report: human nutrition products

    consumed daily containing a total 500 milligrams of ZIVO algae, among other healthful ingredients. Unlike nutraceuticals or over the counter medications, this nutritional product is intended for long-term use over the course of many months without the downside effects of traditional anti-inflammator

  6. Slide 6: President's Report: bovine mastitis research

    The bovine mastitis research has been moving toward its final phase of validation for well over 2 years, as we faced challenges ranging from contaminated samples that created months of delays to the availability of scientists to conduct analytics in what is a very specialized field of research. At t

  7. Slide 7: President's Report: dairy cow testing

    The samples with the best results from the Michigan State in vitro experiments will then be introduced to infected dairy cows in what we hope will be the last experiment in the discovery process. If that final test is successful, we’ll wrap up this research and present it to our collaboration partne

  8. Slide 8: President's Report: ZIVO laboratory in Michigan

    and agtech’s is that we’re not married to a single product, a single course of action, a particular field of science, or even the expertise of one individual. However, we are making one exception and that is availability of our algal biomass, either in small quantities for experimentation or as a vi

  9. Slide 9: President's Report: Wellness Panel patent

    At last year’s shareholders meeting, we stated that with a budget hovering near zero, we had made improvements in product design, conducted finite element analysis of the urine sample collection device and largely finished the CAD modeling necessary for tooling to produce finished pieces. Most impor

  10. Slide 10: Welcome - ZIVO Bioscience Annual Shareholder Meeting

    ZIVO Bioscience Annual Shareholder Meeting WELCOME May 1, 2019 Detroit, Michigan

  11. Slide 11: Notice: Safe Harbor Statement

    Notice Safe Harbor Statement Except for any historical information, the matters discussed in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements i

  12. Slide 12: CFO Report

    2019 Annual Shareholder Meeting May 1, 2019 Detroit, Michigan WELCOME Meeting Open CFO REPORT Philip M. Rice II Chairman & Chief Financial Officer

  13. Slide 13: Report to Shareholders

    2019 Annual Shareholder Meeting May 1, 2019 Detroit, Michigan Report to Shareholders Andrew A. Dahl President & Chief Executive Officer

  14. Slide 14: Notice to Shareholders and Investors

    2019 Annual Shareholder Meeting Notice to Shareholders and Investors This presentation and any Exhibits to it contain forward-looking statements that involve risks and uncertainties. These statements reflect the Company’s future plans, objectives, expectations and intentions, and the assumptions und

  15. Slide 15: CEO Report: The Last 6 Months

    CEO Report to Shareholders The Last 6 Months Focus on capital funding and global supply chain o Campaign has attracted $5+M in new funding during 2018 o Looking at new sources of investment & partnering o Funding ZIVO research, compliance and production

  16. Slide 16: The Patents are the Assets

    CEO Report to Shareholders ™ kalgaE The Patents are the Assets A significant intellectual property portfolio o Novel methods and uses patents o Valuable nutritional product formulations o Multinational patent/trademark strategy

  17. Slide 17: Value Creation: Use of Proceeds

    Value Creation Use of Proceeds 2018 and into 2019 o Human GRAS November 2018 o Poultry GRAS underway o Building out global supply chain

  18. Slide 18: Value Creation: A Stronger Balance Sheet

    Value Creation A Stronger Balance Sheet Benefits of converting debt to equity o Attract significant new investment o Non-dilutive financing of WIP and inventory o Accelerate market entry and revenues

  19. Slide 19: Value Creation

    Value Creation Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes The hottest technology sector for global investors o Breakthrough poultry studies o Visibility with global entities o Resources allocated to opportunities at hand

  20. Slide 20: Global Supply Chain

    Global Supply Chain Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Acting on Global Market Opportunities o Letters of Intent with Indian, Peruvian, Chinese growers o Product registration, import/export approvals o Intellectual property protection top priority

  21. Slide 21: Global Supply Chain: Market Opportunities

    Global Supply Chain Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Acting on Market Opportunities o 40 growers can produce ~ 11,000 metric tons annually o ZIVO sells to poultry producers @ $12,000/metric ton o Approx. $132,000,000 in annual revenues for a single US market vertical o

  22. Slide 22: Global Supply Chain: Alimenta Peru

    Global Supply Chain Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Acting on Market Opportunities o Alimenta – Peru S.A.C. o Largest poultry producer in South America o Convert spirulina production to ZIVO algae o Potential JV to build/operate 280-pond facility

  23. Slide 23: Poultry Feed Ingredient: Compliance & Registration

    Poultry Feed Ingredient Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Compliance & Product Registration – US & EU o Tox Strategies engaged for poultry GRAS o Specie-specific safety/toxicology study o 6-month product stability study o Pen & Tec engaged for EU poultry feed registrati

  24. Slide 24: Poultry Feed Ingredient: Groundbreaking Phytogenic

    Poultry Feed Ingredient Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Groundbreaking Phytogenic o Exceptional results from numerous studies o Different studies, different researchers, same results o Improvements in animal health and productivity o Econometrics indicate significant

  25. Slide 25: Poultry Feed Ingredient: Phytogenic Feed Ingredient

    Poultry Feed Ingredient Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Phytogenic Feed Ingredient o Broilers consume ~61 billion pounds of feed in US o ZIVO sells to poultry producers @ $12,000/metric ton o Approx. $132,000,000 in revenues on 11,000 tons for a single US market verti

  26. Slide 26: Human Health & Wellness: Skin Health

    Human Health & Wellness Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Phytogenic Skin Health Ingredient GREKIN LABORATORIES o Unique product formulations o Clinical trials to substantiate claimed benefits o JV arrangement provides better margins o Established brand and distribution

  27. Slide 27: Human Health & Wellness: Joint Health

    Human Health & Wellness Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Phytogenic Joint Health Ingredient o Unique product formulation o Clinical trials to support product claims o Digital marketing partnership promises better margins o Established brand, distribution, order process

  28. Slide 28: Human Health & Wellness: Health Snack

    Human Health & Wellness Algal Biomass AgTech Extracts Agricultural Technology Dry Mixes Phytogenic Health Snack Ingredient o Highest % of algae in any snack on the market o Great taste, no odor, good product stability o Non-GMO, soy-free, gluten-free, animal-free, dairy- free, pesticide/herbicide-fr

  29. Slide 29: Human Health & Wellness

    Human Health & Wellness

  30. Slide 30: Research & Development: Bovine Mastitis Candidates

    Research & Development Biotech Biotechnology Molecules Compounds Complexes Bovine Mastitis Therapeutic Candidates o A global animal health and productivity issue o Quest for non-antibiotic alternative treatment o A massively parallel research effort involving universities, independent labs and CRO’s

  31. Slide 31: R&D: National Center for Natural Products Research

    Research & Development Biotech Biotechnology Molecules Compounds Complexes National Center for Natural Products Research o A new, novel molecule that inhibits TLR-4 receptors o Purification process costly and time-consuming

  32. Slide 32: R&D: NCNPR TLR-4 molecule testing

    Research & Development Biotech Biotechnology Molecules Compounds Complexes National Center for Natural Products Research o A new, novel molecule that inhibits TLR-4 receptors o Purification process costly and time-consuming o To be tested with other bioactive candidates in dairy cows after extensive

  33. Slide 33: R&D: Dairy Experts, LLC

    Research & Development Biotech Biotechnology Molecules Compounds Complexes Dairy Experts, LLC – Tulare, CA o Pre-pilot completed with new pathogen target o Results to be announced shortly o Preparatory step for final round of testing o Conclusion of discovery stage R&D

  34. Slide 34: Why This Matters

    Why This Matters Biotech Biotechnology Molecules Compounds AgTech Algal Biomass Extracts Complexes Agricultural Technology Dry Mixes ZIVO algae and its extracts can bridge across biotechnology and agricultural technology to offer improved immune health, improved digestive health and improved respons

  35. Slide 35: Research Strategy

    Research Strategy Biotech Biotechnology Molecules Compounds AgTech Algal Biomass Extracts Complexes Agricultural Technology Dry Mixes Virtualized, Decentralized R&D Approach o No internal research facilities o Inconsistent funding o Pick and choose the best available talent o Manage and optimize the

  36. Slide 36: Research Strategy: Michigan Life Sciences & Innovation Center

    Research Strategy Biotech Biotechnology Molecules Compounds AgTech Algal Biomass Extracts Complexes Agricultural Technology Dry Mixes Michigan Life Sciences & Innovation Center o Local wet lab to produce inoculum o Controlled experimentation o Lab-scale processing such as drying, desiccating o Suppo

  37. Slide 37: Progress in the Last 6 Months

    Progress Biotech Biotechnology Molecules Compounds AgTech Algal Biomass Extracts Complexes Agricultural Technology Dry Mixes In the Last 6 Months o Human GRAS o GRAS/AAFCO poultry compliance underway o EU product registration underway o Production scaling and early samples from India

  38. Slide 38: Wellmetrix: Get to Know Your Body Better

    wellmetrix Get to Know Your Body a

  39. Slide 39: Disposable Test Cartridge, Wireless Analyzer, Mobile App

    Disposable Test Cartridge Wireless Analyzer Mobile App

  40. Slide 40: Unprecedented Insights Into Personal Health

    Unprecedented Insights Into Personal Health

  41. Slide 41: Progress to Date

    Progress to Date  MDA assay in development  Other assays in validation, pending funding  Analyzers in beta mode, math ready for tooling  Analytic App in demo mode  New Vice-President on board

  42. Slide 42: CEO Report: The Next 6 Months

    CEO Report to Shareholders The Next 6 Months Aggressive Growth on the Horizon o Global footprint o International partnering o The prospect of significant revenue

  43. Slide 43: Q&A

    2019 Annual Shareholder Meeting May 1, 2019 Detroit, Michigan Q&A

  44. Slide 44: Thank You

    ZIVO Bioscience Annual Shareholder Meeting THANK YOU May 1, 2019 Detroit, Michigan

ZIVO Bioscience — Shareholder Meeting (May 2019) on 6ix